Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsDominik Heger - Head of Investor RelationsHassan Al-Wakeel - DirectorHelen Giza - CEO and Chair of the Management BoardMartin Fischer - CFOConference Call ParticipantsGraham Doyle - Executive Director and Equity Research AnalystHugo Solvet - Research AnalystVeronica Clark - AnalystNone - AnalystNone - AnalystOperatorLadies and gentlemen, welcome to the Report on the Fourth Quarter and Financial Year 202 ...

Summary of Fresenius Medical Care FY Conference Call Company Overview - **Company**: Fresenius Medical Care (NYSE: FMS) - **Industry**: Kidney care and dialysis services Core Points and Arguments 1. **Strategic Direction**: Fresenius Medical Care is focused on driving profitable growth and long-term value creation, with 2026 marked as a transition year for implementing a new standard of care in the U.S. through large-scale clinic conversions to a new therapy [2][12] 2. **Industry Fundamentals**: The kidney care industry fundamentals remain strong, driven by an aging population and chronic conditions like hypertension and diabetes, which support global demand for kidney replacement therapies [3] 3. **Pharmaceutical Advancements**: New drugs, particularly GLP-1s, show promise in improving cardiovascular health and reducing mortality in chronic kidney disease (CKD) patients, with a reported 23% improvement in mortality for dialysis patients using these drugs [4] 4. **Market Position**: Fresenius Medical Care is a market leader with over 290,000 patients and 3,600 clinics globally, managing over $7 billion in medical costs and holding a 40% market share in in-center hemodialysis (HD) products [5] 5. **Operational Efficiency**: The company has improved its operating margin from 7.9% in 2022 to 10.3% in 2025, supported by the FME25+ transformation program, which is expected to deliver €790 million in sustainable savings by 2025 [8] 6. **Shareholder Returns**: The 2024 dividend payment was the highest in company history, reflecting a 13% CAGR since 2022, alongside a €1 billion share buyback program initiated in 2025 [9] 7. **Debt Management**: The net leverage ratio has been reduced from 3.4 times in 2022 to 2.6 times by Q3 2025, indicating improved financial health [10] 8. **FME Reignite Strategy**: This new strategy aims to enhance core operations, drive growth and innovation, and strengthen company culture, with aspirations for mid-teen margins by 2030 [12][13] Additional Important Insights 1. **Patient Care Focus**: The company is addressing patient outflow issues by enhancing treatment adherence and reducing missed treatments, which have been exacerbated post-COVID [29][30] 2. **HDF Therapy Rollout**: The introduction of high-volume HDF therapy is expected to significantly improve patient outcomes, with a target to convert 20% of machines in clinics by 2026 [19][20] 3. **Market Dynamics**: The company is navigating challenges such as elevated mortality rates and missed treatments, while also adapting to changes in ACA subsidies that may impact patient behavior [26][35] 4. **Innovation Pipeline**: The 5008X machine rollout is a key innovation, with production capacity of 15,000 machines per year, aimed at enhancing patient care and operational efficiency [17][45] 5. **Long-term Growth Outlook**: The company anticipates robust cash flow generation, projecting operating cash flow above €2.5 billion annually through 2030, supporting its growth and shareholder return strategies [23][27] This summary encapsulates the key points discussed during the Fresenius Medical Care FY Conference, highlighting the company's strategic initiatives, market position, and outlook for future growth.

Financial Performance - The company reported third quarter adjusted operating income of $517 million and adjusted earnings per share of $2.51, consistent with internal expectations [6][11] - Free cash flow for the quarter was $604 million, indicating strong cash generation capabilities [11] - Full-year adjusted operating income is anticipated to be between $2.035 billion and $2.135 billion, with adjusted earnings per share projected at $10.35 to $11.15 [8][16] Business Line Performance - U.S. dialysis treatment volume declined approximately 1.5% year-over-year, attributed to a mix of treatment days and external factors such as a severe flu season and Hurricane Helene [6][11] - Revenue per treatment increased by approximately $6 compared to the second quarter, driven by rate increases and higher revenue from phosphate binders [11][12] - Patient care costs per treatment increased by approximately $5 sequentially, primarily due to wage increases and higher pharmaceutical expenses [12][13] Market Dynamics - The company is closely monitoring the impact of enhanced premium tax credits on the commercial payer mix, which could significantly influence revenue [9][22] - The ongoing recalibration of the Medicare Advantage landscape is also a key factor affecting enrollment and insurance mix [9][22] Strategic Direction - The company is investing in technology infrastructure, including enhancements to its clinical platform and the adoption of AI solutions, aimed at improving patient care and operational efficiencies [7][10] - Long-term investments in IT and clinical innovation are expected to strengthen the company's ability to deliver superior patient care [10][61] Management Commentary - Management acknowledged the challenges posed by the government shutdown and its implications for healthcare policy, but emphasized a focus on delivering excellent care [4][6] - The company remains optimistic about its ability to navigate upcoming challenges and is committed to achieving its full-year goals [10][61] Other Important Information - The company repurchased 3.3 million shares during the third quarter and an additional 400,000 shares since, totaling approximately $1.5 billion year-to-date [15][16] - The leverage ratio at the end of the quarter was 3.37 times consolidated EBITDA, within the target range [16] Q&A Session Summary Question: Impact of one-time items on volume - Management estimated a 75 to 100 basis point headwind on 2025 volume due to Hurricane Helene, the cyber incident, and the severe flu season [18] Question: Improvement in mortality rates - Management indicated that improvements in mortality are expected to be gradual and are focusing on clinical protocols to address this issue [19] Question: Medicare Advantage enrollment dynamics - Management highlighted that shifts in membership between payers could significantly impact revenue, emphasizing the current volatility in the marketplace [20][21] Question: Treatment growth and new patient starts - Management noted that treatment volume for the quarter came in as expected, with some pressure on mistreatment rates due to the cyber attack [43] Question: Timing of Integrated Kidney Care (IKC) funds - Management explained that the timing of IKC revenue recognition is difficult to predict and is influenced by when information is received from payers and the federal government [46][47] Question: Market share trends - Management stated that there have been no significant shifts in market share, even when accounting for the impacts of the cyber incident [50][51]